MarginsXMarginsX
Home › Markets › Health Care › ZBIO

Zenas BioPharma Inc. (ZBIO)

ZBIO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$27.93
-0.29% on the day
Market cap
$1.9B
Small cap
Revenue · 2025
$10.0M
+100.0% on 2024
Net income · 2025
-$377.7M
-3777.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1953926/000110465926027964/0001104659-26-027964-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerZBIO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2024
SEC CIK0001953926
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$10.0M
Net income-$377.7M
Operating income-$383.1M
Net margin-3777.4%
Operating margin-3830.6%
Revenue growth+100.0%
Cash$110.6M
Total assets$383.6M
P/E (computed)Net income was not positive
P/S (computed)189.4×

Warning signs

Cash runway
8.8 months
$177.8M cash at September 30, 2026
Share count, 1 year
+26.3%
2025-10-31 to 2026-10-30
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$27.8M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$177.8M cash; operating cash flow -$60.7M a quarter.Report 2026-09-30
Shares outstanding67,817,793 (2026-10-30); 53,679,166 a year earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 5 424B5 takedowns, 5 at the marketLatest 2026-11-06
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-04-01
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $27.8M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$10.0M-$108.9M-$58.0M$177.8MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2026
2026-06-30
$1.0M-$111.5M-$57.2M$196.6MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2026
2026-03-31
Not filed-$81.0M-$75.2M$500.2MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2025
2025-12-31
$0-$240.4M-$52.4M$110.6M$78.6M$10.0M10-K 2026-03-16
Q3 2025
2025-09-30
$0-$51.5M-$41.1M$115.6M$73.0M$15.0M10-Q 2025-11-12
Q2 2025
2025-06-30
$0-$52.2M-$41.7M$44.0MNo debt tags$15.0M10-Q 2025-08-12
Q1 2025
2025-03-31
$10.0M-$33.6M-$37.1M$196.6MNo debt tags$15.0M10-Q 2026-05-13
Q4 2024
2024-12-31
$5.0M-$52.6M-$38.6M$319.7MNo debt tags$5.0M10-K 2026-03-16

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-11-06
Latest annual report10-K2026-03-16
Latest quarterly / interim10-Q2026-11-05
Latest current report
FORM 8-K
8-K2026-11-06
Latest proxyDEFA14A2026-03-16

Source: SEC EDGAR submissions feed, 196 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-0.9%
1 month+11.3%
3 months-4.1%
Year to date-22.9%
1 year-21.5%
From 52-week high-35.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
TRVITrevi Therapeutics Inc.$13.29-2.64%$1.9B
MRVIMaravai LifeSciences Holdings Inc.$7.40-1.86%$1.9B
HRMYHarmony Biosciences Holdings Inc.$32.96-2.37%$1.9B
ETONEton Pharmaceuticals Inc.$63.88-0.08%$1.8B
VERAVera Therapeutics Inc.$26.97-4.02%$1.9B
TRAXFirst Tracks Biotherapeutics Inc. Ordinary Shares$46.56-1.15%$2.0B
ZYMEZymeworks Inc.$26.45+0.80%$1.8B
SEPNSepterna Inc.$41.67-2.18%$2.0B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier